At CHEST 2016, an abstract was published in which ResMed shared evidence that people who use a self-management app when treating their sleep apnea with positive airway pressure (PAP)/continuous positive airway pressure (CPAP) are significantly more likely to stick with their therapy.
Now the study is being published in the peer-reviewed journal CHEST. The study as it is accepted for publication was published online on Nov 15 and will also appear in upcoming print issue. The CHEST-published paper contains more details than the 2016 abstract.
The research included more than 128,000 patients.
PAP users whose nightly use was remotely and self-monitored via ResMed’s AirView and myAir platforms, respectively, were more than 87% adherent on therapy, compared to 70% of those only remotely monitored (a 24% relative increase).
Self-monitoring was also linked to increased nightly use: Patients using myAir and AirView together used PAP an average hour more per night—5.9 hours a night, compared to 4.9 hours for the remotely monitored-only group.
“CHEST’s publication is a significant call for clinicians to recommend self-monitoring tools for PAP patients,” says ResMed Chief Medical Officer Carlos M. Nunez, MD, in a release. “I also believe these tools could help patients on therapies beyond sleep as well, since half of all patients don’t take their medications as prescribed.”